Adimab Continues Roll-out of Its Technology Transfer Program with Novo Nordisk – 3rd Transfer in 2013
Lebanon, New Hampshire, USA – September 26, 2013 – Adimab, LLC, a leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced its 3rd technology transfer, by licensing the Adimab technology to Novo Nordisk. Adimab will receive upfront payments, annual licensing fees, and royalties on commercialized products resulting from Novo Nordisk’s use of the Adimab technology. Under the agreement, Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.
By the first quarter of 2014, Adimab expects to have deployed its technology to three partner sites (GSK, Biogen Idec and Novo Nordisk). Adimab forecasts additional transfers throughout 2014, driven by the broad interest in its technology transfer program.
“We are pleased to have expanded our partnership with Novo Nordisk,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “This is the third platform transfer this year, and this transaction with Novo Nordisk further validates our view that leading pharma companies have a need for better antibody discovery and optimization tools. At this point in time, our platform is the leading technology for antibody discovery and optimization, but, we haven’t rested on our laurels; we have over 25 people working on improving and expanding the platform’s capabilities to make sure that we stay ahead of the field.”
“We are very pleased to have established a broad relationship with Adimab,” said Hanne Risager Romedahl, Vice President of Novo Nordisk. “We feel confident that Adimab offers a comprehensive solution for our antibody discovery needs. In addition to using the platform as a rapid IgG discovery engine, we are particularly impressed with the ability to optimize antibodies with this broad protein engineering tool. This capability will nicely complement and enhance our existing antibody discovery technologies.”
Under the terms of the agreement, Novo Nordisk will have a non-exclusive field license to the Adimab antibody discovery platform and a unique custom antibody library that is exclusive to Novo Nordisk. Novo Nordisk is allowed to use the Adimab platform on an unlimited number of targets for IgG discovery, optimization, humanization and bispecifics. In addition, Novo Nordisk may access improvements to the platform during the term of the collaboration. Adimab will receive a series of payments including upfront payments, research and development milestones, plus royalties and commercial milestones on all therapeutic products generated from the Adimab platform.
“We are very proud that yet another Adimab partner has expanded into a broader relationship after seeing the output from the Adimab platform on several therapeutic projects,” said Guy Van Meter, VP of Business Development at Adimab. “This Novo Nordisk deal is another example of how we are able to structure terms around our partner’s needs and intended scope of use. We are looking forward to a productive partnership with Novo Nordisk.”
Over the past four years, Adimab has established numerous partnerships with leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, Kyowa Hakko Kirin, GSK, and Celgene. Adimab’s partnerships range from single-target funded discovery projects, to larger multi-target funded discovery collaborations. In 2013, Adimab started transferring its antibody discovery platform and custom antibody libraries to pharmaceutical companies for internal use. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.